Anavex Life Sciences Corp. (AVXL )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol AVXL
- Company Anavex Life Sciences Corp.
- Price $3.52
- Changes Percentage -3.36
- Change -0.1224
- Day Low $3.29
- Day High $4.04
- Year High $14.44
- Year Low $2.86
- Market Cap $301,487,357
- Price Avg 50 EMA (D) $8.5
- Price Avg 200 EMA (D) $9.07
- Exchange NASDAQ
- Volume 5,191,675
- Average Volume 1,701,935
- Open $3.51
- Previous Close $3.65
- EPS -0.57
- PE -6.16
- Earnings Announcement 2025-11-28 13:30:00
- Shares Outstanding $85,893,834
Company brief: ANAVEX LIFE SCIENCES CORP. (AVXL )
- Healthcare
- Biotechnology
- Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
- https://www.anavex.com
- US
- N/A
- 08-02-2006
- US0327973006
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.